Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by hmmmmmmmmon Feb 22, 2024 1:21am
198 Views
Post# 35892521

They crafted the PR so it reads

They crafted the PR so it readsas a measly "extension of a distribution deal".

Do a Baxter Spectral Google search...  Two or 3 sites will come up- and "extension of distribution deal" will be the headline.

Nothing to see here. 


Nope. The big MILESTONE, the big CATALYST we've been hearing about for years-

It's a "distribution extension". 

Nothing about the new millions Baxter is investing. (15 -20m?)

Baxter won't even mention the Tigris trial- "evidence generation strategy". 

Baxter won't say a word about seeing the trial data/ results on the "90" patients.

It's a "distribution extension". 

That's what management wants you- and the whole world to believe and ignore!


And again curious that Kellum is staying clear- of another PR and tomorrows call..



<< Previous
Bullboard Posts
Next >>